Clinical trials are the backbone of medical progress, serving as the driving force behind the development of new treatments and therapies. Understanding the details of these trials is crucial, as it empowers you to make informed decisions about your healthcare, demystifies the process, and ensures you play an active role in shaping the future of GIST treatment. Featured in this section are a few trials that are currently recruiting for patients with metastatic, advanced or unresectable GIST.
If you would like more information about details of any of these trials, please contact liferaft@liferaftgroup.org
INSIGHT Phase 3
Ripretinib as a second-line treatment for patients
who have failed imatinib and have a KIT exon 11 and a KIT exon 17 and/or KIT exon 18 mutation.
PEAK Trial
Bezuclastinib in combination with sunitinib vs. sunitinib alone, in people with locally advanced,
unresectable, or metastatic GIST who have previously received imatinib.
INBRX-109 Trial
For patients with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors.
Patient Info Sheet (PDF)
Phase 1 StrateGIST
For patients with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors.
Patient Info Sheet (PDF)
Recent Articles about Clinical Trials:
Clinical Trial for Ripretinib
Studies have shown that if you have GIST with mutations in KIT exons 11 and 17/18, ripretinib may be a better option for second-line treatment than the standard sunitinib.
The Impact of Clinical Trials on Treatment Options
Clinical trials are an essential part of medical research, aimed at introducing new procedures and treatments to the public.
What are Clinical Trials & How Do You Find Them?
Clinical trials are scientific research studies done in humans that help us to understand whether a new treatment is safe and effective in treating an illness, such as cancer.
New Clinical Trials Focus for the LRG in 2024
Starting in January, every Wednesday will be dedicated learning about clinical trial process and to highlighting the groundbreaking clinical trials focused on gastrointestinal stromal tumors (GIST).